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Background: Visceral leishmaniasis (VL), also called Kala Azar (KA) or black fever in India, claims around 20,000 lives
every year. Chemotherapy remains one of the most important tools in the control of VL. Current chemotherapy for
Kala Azar in India relies on a rather limited arsenal of drugs including sodium antimony gluconate and amphotericin
B in addition to the very expensive drug miltefosine. Pentavalent antimonials have been used for more than half a
century in the therapy of leishmaniasis as it is relatively safe and inexpensive, however, the spread of resistance to this
drug is forcing clinicians in India to abandon this treatment. Consequently, improvement of antimonial chemotherapy
has become a major challenging area of study by leishmaniacs worldwide. The alarming emergence of resistance to
the commonly used antleishmanial drug, sodium antimony gluconate, in India, has led us to elucidate the resistance
mechanism(s) in clinical isolates. Studies on laboratory mutants have shown that resistance to antimonials is highly
dependent on thiol levels. The parasite evades cytotoxic effects of antimonial therapy by enhanced efflux of drug upon
conjugation with thiols, through overexpressed membrane proteins belonging to the superfamily of ABC transporters.
Methods: We have carried out functional studies to determine the activity of the efflux pumps in antimonial resistant
clinical isolates collected from disease endemic areas in India and also carried out molecular characterization of thiol
levels in these parasites.
Results: Overexpression of the gene coding for γ glutamylcysteine synthetase was observed in these resistant clinical
isolates thereby establishing that thiols represent the key determinants of antimonial resistance. The SbIII/thiol
conjugates can be sequestered by ABC transporter multidrug resistance protein A (MRPA) into intracellular organelles
or can be directly pumped out by an uncharacterized transporter.
Conclusions: Our studies investigating antimonial resistance in different L. donovani clinical isolates suggest that over
functioning of MRP plays a role in generation of antimony resistance phenotype in some L. donovani clinical isolates.
Keywords: Leishmania donovani, Drug resistance, Drug efflux, Thiols, Clinical isolatesBackground
Visceral leishmaniasis (VL, kala-azar) is prevalent in 62
countries with an estimated annual incidence of 500,000
(www.dndi.org). In Eastern India, the State of Bihar and
adjoining areas of West Bengal, Jharkhand and Uttar
Pradesh account for about half the world ? s burden of VL.
A recent report by the Press Trust of India (PTI) states
? Kala Azar stalks Bihar ? and reports that in Patna, the
capital city of Bihar, kala azar has affected an estimated* Correspondence: neeloo888@yahoo.com
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unless otherwise stated.25,000 people and claimed 93 lives. Thirty-one of the
state ? s 38 districts are in its grip. Although the foci of
VL in India is Bihar, West Bengal, Uttar Pradesh and
Jharkhand, cases have also been reported from Gujarat
(west India) [1], Tamil Nadu and Kerala (south India)
[2], and sub- Himalayan parts of north India including
Uttar Pradesh, Himachal Pradesh and Jammu and Kashmir
[3]. Globally, including India, the treatment of VL has
centered around pentavalent antimony compounds (SbV)
for more than seven decades, however, about 65 per cent of
previously untreated patients are unresponsive renderingis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mechanisms have been described in resistant Leishmania
species developed in vitro. The drug SbV can be taken up
by the parasite via an unidentified transporter [5,6]. Sb(V),
a prodrug, have to be converted to Sb(III) in order to be
active. Parasite specific thiol dependent reductase 1 (TDR1)
and ACR2 enzymes were characterized in Leishmania and
was shown to reduce Sb(V) to Sb(III) [7,8]. Alternatively,
there is evidence that a number of thiols, including
parasite-specific thiols such as trypanothione as well as
macrophage-specific thiols such as glycylcysteine, can
reduce Sb(V) to Sb(III) non-enzymatically [9]. The result-
ing SbIII can form conjugates with thiols and inhibit
trypanothione reductase (TR) together leading to increase
of redox potential [10]. The SbIII/thiol conjugates can
be sequestered by ABC transporter multidrug resistance
protein A (MRPA) [11] into intracellular organelles or
can be directly pumped out by an uncharacterised
transporter [12]. Studies investigating antimonial resist-
ance in different L. donovani clinical isolates from our
lab and others have suggested a very heterogeneous
situation. The upregulation of antioxidant pathways in
SSG-resistant parasites was most frequently reported
[13,14]. Increased expression of enzyme tryparedoxin
peroxidase may play an important role in clinical resistance
to antimony. Elevated levels of tryparedoxin peroxidase
in antimony-unresponsive L. donovani field isolates has
been reported in Leishmania braziliensis and Leishmania
infantum [15,16]. A comprehensive characterisation of the
parasite pathways implicated in SSG/SbV/SbIII metabol-
ism using a collection of parasite strains isolated from
Nepalese VL patients established that molecular changes
associated with antimonial-resistance in natural Leish-
mania populations depend on the genetic background
of the Leishmania population, which has resulted in a
divergent set of resistance markers in the Leishmania
populations [17]. Increasing unresponsiveness to Sbv in
India, administered as sodium antimony gluconate (SAG),
has led to successive advent of new drugs [18] however,
all plagued by shortcomings. Affordable and effective
chemotherapy is still beyond reach of the common man
in India. Consequently, this study has been undertaken
to determine the status of efflux pumps and thiols in
antimony unresponsive clinical isolates of L. donovani
collected from the endemic region of Bihar, India. An
understanding of resistance mechanism(s) operating inTable 1 Profile of clinical isolates used in the study




4 2001 01.02.2000clinical isolates might lead us to bring back this molecule
alone or in combination therapy.
Methods
Collection of Leishmania donovani clinical isolates
In our study patients were selected from the disease
non-endemic region of Uttar Pradesh (U.P.) as well as
from highly endemic regions viz. Kala Azar Medical
Research Centre of the Institute of Medical Sciences,
Banaras Hindu University, Varanasi and also from its
affiliated hospital situated at Muzaffarpur, Bihar. The
Ethics Committee of Kala Azar Medical Research Centre
of Banaras Hindu University in Varanasi, India, reviewed
and approved the protocol and written informed consent
was obtained from the subjects participating in the study.
The diagnostic criteria for VL were the presence of LD
bodies (Leishman Donovan) in splenic aspirations
performed and graded as per standard criteria [19].
After diagnosis, the patients were administered a course
of sodium antimony gluconate (SAG) [Albert David,
Calcutta, India] 20 mg/Kg body weight once daily for
30 days. Response to treatment was evaluated by a repeat
splenic aspiration on day 30 of treatment. Patients were
designated responsive based on the absence of fever,
clinical improvement with reduction in spleen size and
absence of parasites in the splenic aspirate while patients
who showed presence of parasites in splenic aspirates were
labelled as antimonial unresponsive. These patients were
subsequently treated successfully with amphotericin B.
Culture conditions
The splenic aspirates of the responsive and unresponsive
patients with VL were inoculated into NNN medium and
passaged every seventh day into a tube containing fresh
NNN medium. Positive cultures were then progressively
adapted to M199 medium supplemented with 15% fetal
calf serum for mass culture. The isolates used in this study
are listed in Tables 1and 2.
Assay for drug sensitivity
Assay for in vitro drug sensitivity to SAG was done as
described [20,21]. We used amastigotes rather than
promastigotes. The promastigote stage in the lifecycle is
not susceptible to two major drugs used clinically, these
being pentavalent antimonial drugs, sodium stibogluco-





Table 2 Profile of clinical isolates used in the study
S. No Isolate Year of collection Place of collection Drug response to SAG
1 93 16.12.2003 Muzaffarpur, Bihar Unresponsive
2 77 05.11.2003 Muzaffarpur, Bihar Unresponsive
3 87 06.12.2003 Balia, U.P. Responsive
4 4 29.11.2004 Balia, U.P. Responsive
5 138 04.02.2005 Deworia, U.P. Responsive
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also confirmed in vivo, by infection in golden hamsters
as described [22].
Nucleic acid isolation and blotting
Nuclear DNA was isolated by established procedure using
proteinase K digestion [23]. Total RNA was isolated using
TRIZOL (Gibco BRL) [24]. Probe for γ-glutamylcysteine
synthetase gene (GCS) was made from PCR amplified
73 bp GCS fragment using primers as described [25].
Alpha tubulin gene primers obtained as a kind gift from
Marc Ouellette, Quebec, Canada were used for amplifica-
tion and probe preparation. Probes were made by labelling
25 ng of the DNAs with [α-32P] dCTP by random priming
method (BRIT/BARC, India).
Flow cytometry
Flow cytometry was employed to ascertain the functional-
ity of ABC transporters in the promastigotes of antimony
unresponsive isolates (39, 41, R-5) and responsive isolate
(2001). Two substrates, Rhodamine 123 (stock: 3 mM in
methanol) was diluted to 100 μM in 0.02 M Phosphate
Buffered Saline pH 7.2 (PBS) and used at a final concen-
tration of 1 μM. Calcein AM (1 mM in DMSO) was
diluted to a final concentration of 1 μM in medium. To
identify the nature of the pump, known modulators of
MDR and MRP namely verapamil (Sigma, St. Louis, USA,
4 mM in PBS, final concentration 10 μM) and probenecid
(Sigma, St. Louis, USA, 0.4 M in PBS, pH 8.5, final
concentration 4 mM) respectively were used.
Fluorescence labelling of L. donovani promastigotes
Log phase promastigotes (2 ? 10 6/ml) were washed twice
with medium M199 (Sigma, St Louis, USA) supplemented
with 10% FBS, 25 mm HEPES pH 7 ? 4 (Medium A) and
incubated at 26?C for fluorescence labelling. Both accumu-
lation and retention assays were done as described [26].
Accumulation assays: Promastigotes (2? 10 6/ml) were
initially washed twice in HEPES buffered saline referred
to as ? HBS1 ? (21 mM HEPES, 137 mM NaCl, 5 mM KCl,
0.7 mM NaH2PO4 and 20 mM glucose, pH 7.4). After
addition of Rhodamine 123, fluorescence was measured at
0, 15, 30 and 45 minutes whereas with calcein AM, fluor-
escence was measured at 0, 15, 30, 45 and 60 minutes. To
study influence of energy depletion upon pump activity,accumulation of both fluorochromes was measured. Pro-
mastigotes were washed twice in HEPES buffered saline
referred to as ? HBS1? (21 mM HEPES, 137 mM NaCl,
5 mM KCl, 0.7 mM NaH2PO4, 20 mM glucose, pH 7.4).
They were transferred to a modified HBS1 where glucose
had been specifically excluded and 20 mM sodium azide
(NaN) included, referred to as ? HBS2? and incubated in
HBS2 at 26?C for 30 minutes and transferred to PBS
containing the fluorescent substrates in the presence or
absence of modulators and readings taken at different
time points.
Retention assays: Promastigotes were pre-loaded with
calcein by incubating them with Calcein AM for 1 h at
26?C. Cells were centrifuged at 3000 g for 5 minutes at
4?C, then washed twice with ice cold Medium A, imme-
diately re-suspended in same medium with or without
probenecid, but notably excluding Calcein AM and
placed on ice. Thereafter, first reading was taken and
was considered as 0 minute reading. Promastigotes were
transferred to 26?C and fluorescence measured at 15, 30,
45, 60 minutes.
Thiol level detection
To measure intracellular thiol levels, Cell Tracker Green
CMFDA (Molecular Probes, stock 10 mM in DMSO;
final concentration 10 μM in serum free medium) was
used. Promastigotes were incubated with Cell- Tracker
both in normal and energy depleted conditions and
fluorescence measured after 45 minutes of incubation at
26?C.
Flow cytometric analysis
Monitoring of dye accumulation and retention was
carried out as described earlier [26] on a flow cytometer
(FACS Calibur, Becton Dickinson) equipped with an
argon-ion laser (15 MW) tuned to 488 nm. Data analysis
was carried out with Cell Quest (BD) software. Fluores-
cence of Rhodamine 123, Calcein AM, and Cell Tracker
were collected in the photomultiplier tube designated
FL1, which is equipped with a 530/30- nm band pass
filter. Filter combination and protocols were used to
generate scatter grams and list mode data on forward vs.
side scatter and counts vs. FL1 height. Samples were
analyzed at the flow rate of 100-200 cells/second and a
typical analysis was based on examination of 10,000
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while cell counts were on a linear scale. Dead cells or
cells with compromised membranes were discriminated
by adding propidium iodide (PI, 5 μg/ml) in every tube.
Fluorescence of PI was taken at photomultiplier tube
designated FL2 equipped with a 585/42-nm band pass
filter. Each result is a representative of four sets of inde-
pendent experiments. For experiments using cell tracker,
in order to eliminate the individual variance of basal
fluorescence of each sample, we have represented the
data as the ratio of fluorescence at any time point divided
by its 0 minute fluorescence and plotted on the Y-axis.
Results
Clinical isolates
During the year 1998-2000, resistance to the widely used
antimonial drug sodium antimony gluconate (SAG) had
reached alarming heights in India [5]. At this time we had
cultivated many unresponsive isolates (Table 1). Isolates
R-5, 39 and 41 are from patient who did not respond to
SAG therapy therefore these are labelled as ? unresponsive? ;
isolate 2001 responded to SAG therapy hence ? responsive? .
Since one of the most frequently applied strategies in
biological systems against resistance to cytotoxic drugs
is the efflux of these compounds from the cell via
membrane proteins, in the present study we have used
these isolates to ascertain their efflux pump phenotype
and to check for amplification and overexpression of
gamma glutamylcycteine synthetase (GCS) gene.
Flow cytometry shows differential expression of ABC
transporters between resistant and sensitive isolates
Using flow cytometry, we have assayed functional activity
of ABC transporters viz. multidrug resistance protein
(MRP) and multidrug resistance gene (MDR) in these
Leishmania isolates. It is anticipated that cells showing a
resistant phenotype would have higher level of energy
dependent pump activity and therefore show less fluores-
cence as compared to cells with normal levels of energy
dependent pumping activity (sensitive isolate). In the pres-
ence of pump modulators, both sensitive and resistant
cells are expected to give similar level of fluorescence.
We discriminated dead cells by addition of propidium
iodide (5 μg/ml). We measured both cellular dye accumu-
lation and dye retention under normal (promastigotes
suspended and assayed in culture medium) as well as ATP
depleted conditions. Time kinetic study of accumulation
of R123 showed that a rapid uptake of R123 occurred in
promastigotes of all the isolates, being maximal in the
antimonial resistant isolate 39 (Figure 1A). With the
addition of verapamil, a known MDR modulator, a con-
sistent decrease was observed in all isolates except R-5
where two fold increase in R123 accumulation was
observed. In order to assess whether ATP influencedthis accumulation of R123, cellular ATP was depleted
by the addition of NaN3 in the incubation buffer. The
removal of ATP did not alter the R123 accumulation as
net fluorescence in the presence or absence of ATP was
no different (Figure1B). Once again, the addition of
verapamil resulted in a decrease in R123 accumulation.
This suggests that Leishmania donovani clinical isolates
lack an energy-dependent classical MDR efflux system
that can be reversed by verapamil. As can be seen from
the accumulation assay, there is no hint of classical
MDR pump activity, therefore, we did not perform the
retention assay of rhodamine. It might be possible that
the effect of verapamil on the accumulation of rhodamine
in R5 may be related to the inhibition of a MDR-type
transporter. With regard to the accumulation of calcein,
39 and 41 showed comparable levels of fluorescence,
with 2001 having marginally higher level of fluorescence
(Figure1C). On the other hand, R-5 had an almost 5
fold reduction in calcein accumulation as compared to
other isolates. Addition of probenecid caused consistent
increase in fluorescence in 2001, 39 and 41; maximal
reversal was observed in 2001 and R-5 showed no alter-
ation in accumulation of calcein. These results indicate
that there is basal level of pumping activity in all clinical
isolates tested but same concentration of probenecid
cannot reverse pump activity to same level as seen in 39.
This indicates that 39 may have some MRP pump activity.
Under energy depleted conditions, calcein accumulation
was greatly enhanced in 2001, 39, 41, the fold increase
being 36.1, 44.0, and 27.3 respectively in comparison to
their levels of accumulation in presence of ATP indicating
that the pump is MRP like (Figure 1D). However R-5
showed only 2.6 fold increase in comparison to normal
level accumulation. With addition of probenecid, the
accumulation of calcein was marginally amplified in 2001
and 39, being 1.3 and 1.1 respectively indicating ATP
depletion itself is sufficient to block the pump activity.
However in 41, a 3.6 fold increase in fluorescence was
observed, therefore, results suggest that in 41 there
maybe change in ATPase level and it still used 10-15%
leftover ATP for efflux after 30 minutes of NaN3 treat-
ment. R-5 continued to show negligible fluorescence.
One is tempted to attribute this to exceptionally higher
level of pump activity. However, the non reversal with
probenecid as also absent of any change following ATP
depletion and disproves our hypothesis. It is conceivable
that in R-5, the passive entry of calcein itself is restricted
or esterase mediated conversion of calcein AM to calcein
is altered. Assay of esterase activity in all isolates showed
similar levels suggesting that lower calcein fluorescence
observed in R-5 is not due to any esterase modification
(data not shown). In the retention assay, cells were pre-
loaded with calcein AM, washed and then incubated in
calcein AM free medium in the presence or absence of
Figure 1 (See legend on next page.)
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Figure 1 Comparison of Rhodamine and Calcein accumulation with retention in L. donovani clinical isolates. (A) Rhodamine accumulation in
promastigotes of sensitive (2001) and resistant (39, 41, R-5) isolates under normal condition after 45 minutes of incubation. (B) Rhodamine accumulation
in promastigotes of sensitive (2001) and resistant (39, 41, R-5) isolates under ATP depletion after 15 minutes of incubation. (C) Calcein accumulation in
promastigotes of sensitive (2001) and resistant (39, 41, R-5) isolates under normal condition after 60 minutes of incubation. (D) Calcein accumulation
in promastigotes of sensitive (2001) and resistant (39, 41, R-5) isolates under ATP depletion after 30 minutes of incubation. (E) Calcein retention in
promastigotes of sensitive (2001) and resistant (39, 41, R-5) isolates without probenecid. (F) Calcein retention in promastigotes of sensitive (2001) and
resistant (39, 41, R-5) isolates with probenecid. Data shown are results from 1 experiment and representative of 3 independent experiments.
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calcein being retained within the parasites, which would
indirectly reflect MRP activity. As seen in (Figure 1E and F)
at 60 minutes, the sensitive isolate 2001, showed maximum
retention of calcein as compared to the resistant isolates 39,
41, and R-5. Amongst the resistant isolates, 39 showed
minimum calcein retention at each time point that was
most pronounced at 60 minutes indicating maximum
efflux activity that was validated by reversal with probene-
cid. In all isolates, probenecid enhanced retention of cal-
cein indicating presence of MRP like pump.Thiol levels
Measurement of total intracellular thiol levels in energy
depleted conditions in strains indicated that 39 and 41
show greater thiol level than 2001 and R-5 showed least
level of thiol whereas under normal conditions thiol
levels were 41 > 2001 > 39 > R-5 (Table 3).Amplification and overexpression of γ glutamylcysteine
synthetase (GCS) gene
Equivalent amount of DNAs were digested with various
restriction enzymes. Southern blotting using probe span-
ning γ glutamylcysteine synthetase (GCS) showed distinct
amplification of the gene in SAG unresponsive isolates 39
and R-5 as opposed to responsive isolate 2001 (Figure 2A).
Using the same probe, northern blotting showed an
increased expression of two transcripts of 2.4 and 3.4 kb
only in SAG unresponsive isolate 39 (Figure 3A). Amongst
the isolates, 138, 93, 87, 77, 4; gene amplification was
observed in 93, 87 and 4 (Figure 4B) and gene overex-
pression was seen in 93 and 87 (Figure 5A).Table 3 Times increase of total thiol levels in promastigotes
of SAG resistant isolates 39, 41, R-5, with respect to the
SAG sensitive isolate 2001 as calculated by the ratio of
fluorescence of resistant isolates to sensitive isolate




Data shown are results from 1 experiment and representative of 3
independent experiments.Discussion
As illustrated in Table 1, we collected clinical isolates
from the eastern region of India. We confirmed that no
new strain responsible for drug unresponsiveness has
emerged during this period [27]. This re- confirms the
finding established during 1998-1999 [28]. We also estab-
lished in these isolates that susceptibility to sodium
antimony gluconate (SAG) as determined in vitro with
intracellular amastigotes correlated with the clinical
response [20]. The specific chemotherapeutic response of
these isolates was persistent even after repeated passages
in cultures as promastigotes and in vivo in experimental
models [22] which again indicates that these isolates
are truly refractory to SAG treatment in field conditions.
Having established that resistance to SAG in clinical
isolates is stable, our isolates are maintained in antimony
free medium throughout. Although certain reports indicate
that there is stage specificity to antimony susceptibility
[29], our study [20,22] established the fact that promasti-
gotes are not altogether unresponsive to SAG but do show
an intermediate susceptibility phenotype to antimony
thus justifying the use of promastigotes as a preliminary
screen to verify research methods and pinpoint poten-
tially important genes using a stage that is easily grown
in culture, and not contaminated by host material.
Rhodamine/calcein uptake experiments are well estab-
lished assays for detecting functional activity of MDR
and MRP efflux pumps. These assays have extensively
been used in cancer therapy where calcein AM, when
used in a retention assay with MRP1 specific modulators,
is able to reliably detect MRP functional activity [30] and
similar strategy employed for Leishmania cells [31]. How-
ever, we must keep in mind that there is yet no published
evidence that Sb and these substrates use the same trans-
port pathways in Leishmania. In vinblastine and flavone
resistant Leishmania strains the status of drug efflux
pump MRP, has been studied using rhodamine 123
(Rh123) specific blockers to check the specificity of
active efflux system, viz probenecid (blocker of MRP) and
verapamil (blocker of MDR) [32,33]. Functional assays
for analysis of MDR-related protein expression by flow
cytometry have also been described [34]. The methodology
for the determination of kinetics of these fluorochromes
and modulators and parameters to use has been described
and validated previously in the case of mammalian cells.
Figure 2 Southern blot analysis for detection of (A) γ glutamylcysteine synthetase (GCS) gene amplification (B) same blot with α-tubulin
gene probe.
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Figure 3 Northern blot analysis for detection of (A) γ
glutamylcysteine synthetase (GCS) gene overexpression (B)
α-tubulin gene probe (C) EtBr stained rRNA bands showing
equal loading.
Figure 4 Southern blot analysis for detection of (B) γ
glutamylcysteine synthetase (GCS) gene amplification (A)
same blot with α-tubulin gene probe.
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by performing experiments at 25?C and using higher cell
number. A number of prior experiments by spectrofluo-
rometer were done to reach the satisfactory concentration
giving good accumulation/retention of fluorochrome within
cells. To deplete intracellular ATP pools, the parasites were
pretreated with 20 mM NaN3 and this is an established
protocol used in Leishmania cells giving more than ~90%
depletion [35]. Under chilled conditions, where endocytosis
is prevented, as compared to sensitive, the resistant para-
sites showed decreased accumulation.
Using these well established functional assays, our data
suggests that over functioning of MRP plays a role in
generation of antimony resistance phenotype in some
L. donovani clinical isolates. A striking difference frommammalian MRP2 localisation is that the MRPA trans-
porter of Leishmania is an intracellular protein and it
confers resistance to antimonials by sequestration of
the metal thiol conjugates in an intracellular organelle
located close to the flagellar pocket [36,37]. Resistance
is due to enhanced efflux of the drug from the parasite
from its flagellar pocket region, which is a major site
for exocytosis-mediated process. We could establish that
SAG unresponsive isolate 39, has developed resistance
by an increased MRP like pump activity, and showed
maximally increased levels of thiols as estimated by flow
cytometry and detected by GCS gene overexpression. This
indicates towards increased formation of metal thiol
adducts and its sequetration by the ATP coupled MRP
pump. It has been documented that antimony forms
conjugate with cellular thiols and is then extruded by
MRP [38]. In comparison to 39, in isolate 41, less MRP
activity was observed which was greatly reversed by pro-
benecid, therefore, results suggest that in 41 there maybe
change in ATPase level and it still used 10-15% leftover
ATP for efflux after 30 minutes of sodium azide treatment.
SAG unresponsive isolate R-5, did not show any MRP
pump activity and had lowest thiol levels and showed no
overexpression of GCS gene in comparison to other SAG
unresponsive isolates. This is in accordance to our analogy
that membrane modification alone is the factor conferring
resistance in this isolate [39]. Therefore, isolate 39 was
confirmed to be maximally SAG resistant in comparison
to isolate 41 and R-5.
Since, as established in arsenite resistant mutants,
amplification of GCS gene is linked to an increase in the
levels of GSH and TSH [40], the thiols cysteine, glutathi-
one (GSH) and trypanothione (TSH) have been earlier
Figure 5 Northern blot analysis for detection of (A) γ
glutamylcysteine synthetase (GCS) gene overexpression (B)
α-tubulin gene probe (C) EtBr stained rRNA bands showing
equal loading.
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Quantification of thiols showed no differences in TSH
levels between resistant and sensitive isolates, however,
cysteine levels were increased in 39 when compared to
2001. GSH levels were increased in resistant isolates 39 and
41 when compared to 2001. Elevated levels of tryparedoxin
peroxidase were also observed in these antimony unrespon-
sive isolates (unpublished communication). Independentresearch groups in India who used our isolates also report
that there is no classical MDR pump activity [43] and
report amplification of MRPA, GCS and ODC both at
genetic and transcriptional level. It has been shown that
GCS expression is upregulated in SAG unresponsive
parasites [44].
We added five new isolates namely 93, 77, 87, 4 and 138
to our repertoire (Table 2). At the time of their collection,
because of the increasing antimonial drug resistance
problem, treatment with SAG had been discontinued
by our clinical collaborator. Isolates 87,4 and 138, were
classified as being responsive solely due to the fact that
these patients were from a region of India, namely
Uttar Pradesh where so far antimonial drug resistance
has not been reported to be present in comparison to
the highly drug resistant endemic area of Bihar. So
these isolates had actually not received SAG treatment
by clinician but still have been categorized as respon-
sive or unresponsive because of their origin from well
acclaimed geographic region endemicity being resistant
or sensitive. But when we checked for the in vitro drug
sensitivity to SAG of these parasites in our laboratory
(data not shown) we found that isolate 4 and 138 were
indeed responsive/sensitive to drug thus conforming to
the clinician? s criterion. However 87, turned out to be con-
trary to the clinician? s expectation. It showed in vitro drug
resistance to SAG. It is possible, and we have frequently
observed this in the field, that this patient 87 although
hailing from a SAG sensitive area, would have taken this
drug for treatment himself, as this drug is cheap and easily
available over the counter. But since he was not cured,
therefore showing in vitro drug resistance to SAG,
reported to the clinician for subsequent treatment with
amphotericin B. Isolates 93 and 77 were confirmed to be
unresponsive to SAG in the laboratory.
SAG unresponsive isolate 93 showed both amplifica-
tion and overexpression of GCS gene along with high
intracellular thiol levels as assessed by Cell Tracker and
MRP activity (data not shown). The other SAG unrespon-
sive isolate 77 indicates towards resistance mechanism
similar with R-5. Two SAG responsive isolates, 87 and 4
showed amplification of GCS gene with overexpression
of gene only observed in isolate 87 which also showed
increased total thiol levels. It has been reported in
Leishmania that the amplification of gene does not
always seem to lead to an increase in RNA levels. Thus
one interesting observation brought out in our study is
that the overexpression of GCS gene in Northern in
isolate 87 resulted in resistance and also conforming to
in vitro drug sensitivity profile of this isolate whereas
the decreased expression of this gene as detected by
Northern blotting in isolate 4, although showing corre-
sponding gene amplification in Southern blotting, was
followed by sensitivity to the drug.
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We speculate by analogy to the thiol linked proposed
resistance mechanism in laboratory mutants, that an-
timony unresponsive clinical isolates are also associated
with elevated thiols and subsequently with enhanced
MRP activity.
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